3B Future Health Fund — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

OncoResponseoncoresponseinc.comApr 2025 · $14M

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

BiotechHouston, US

Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)

BoardSteven Gillis(Director)in

Board seatRoberto De Ponti· per SEC Form D

Co-investorsCanaan Partners GreatPoint Ventures RiverVest Venture Partners Alexandria ARCH Venture Partners Bering Capital +5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.